Literature DB >> 25373448

Persistent hypertension in lupus nephritis and the associated risk factors.

Syahrul Syazliana Shaharir1, Ruslinda Mustafar, Rozita Mohd, Mohd Shahrir Mohd Said, Halim A Gafor.   

Abstract

Arterial hypertension (HPT) burden up to two third of systemic lupus erythematosus (SLE) patients and contributes to accelerated atherosclerosis and cardiovascular (CV) risk. We aim to determine the prevalence of HPT among lupus nephritis (LN) patients who were in complete remission (CR) for a minimum of 6 months, with estimated glomerular filtration rate (eGFR) of >60 mL/min/1.73 m(2). This is a cross-sectional study of 64 LN patients who attended Nephrology/SLE Clinic at The National University of Malaysia Medical Centre (UKMMC). Persistent hypertension (blood pressure (BP) ≥140/90 mmHg for at least two occasions), CR for a minimum of 6 months and eGFR of >60 mL/min/1.73 m(2) were identified. Univariate and multivariate analyses were performed to determine the demographic and disease characteristics associated with HPT. Thirty-four of them (53.1 %) were hypertensive. Persistent HPT was associated with disease duration, acute kidney injury and high BP at the onset of LN, longer duration interval to achieve CR, number of relapses and cyclosporine A (CyA) use. There were no associations between histological classes, nephrotic range proteinuria, body mass index and waist circumference with HPT. Factors independently associated with HPT were disease duration OR 1.06 [95 %CI (0.91-1.24)], longer duration interval to achieve CR OR 1.104 [95 %CI (1.02-1.19)], number of relapses OR 2.53 [95 % CI (1.01-6.3)] and CyA use OR 5.3 [95 % CI (1.14-23.9)]. The prevalence of HPT among LN is high despite in remission. Aggressive treatment is important to achieve early CR and to prevent relapses.

Entities:  

Mesh:

Year:  2014        PMID: 25373448     DOI: 10.1007/s10067-014-2802-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  30 in total

1.  Renal haemodynamic characteristics in patients with lupus nephritis.

Authors:  M Nakano; M Ueno; H Hasegawa; T Watanabe; T Kuroda; S Ito; M Arakawa
Journal:  Ann Rheum Dis       Date:  1998-04       Impact factor: 19.103

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Evaluation of clearance studies in lupus nephritis.

Authors:  J L Rosenbaum; M Akhtar; M S Kramer; R M Raja; R Manchanda; N Lazaro
Journal:  Clin Nephrol       Date:  1974       Impact factor: 0.975

4.  Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure.

Authors:  Mikkel Faurschou; Henrik Starklint; Poul Halberg; Søren Jacobsen
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

5.  Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome.

Authors:  C C Mok; R W Wong; C S Lau
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

6.  Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients.

Authors:  S Sazliyana; M S Mohd Shahrir; C T Norella Kong; H J Tan; B B Hamidon; M T Azmi
Journal:  Lupus       Date:  2011-08-15       Impact factor: 2.911

Review 7.  Circulating endothelial cells and vascular injury in systemic lupus erythematosus.

Authors:  R M Clancy
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

8.  The dissociation of arterial hypertension and lupus glomerulonephritis in systemic lupus erythematosus.

Authors:  J Petrin; B Rozman; P Dolenc; D Logar; B Bozic; A Vizjak; D Ferluga; P Jezersek
Journal:  Blood Press       Date:  1993-06       Impact factor: 2.835

9.  Serum leptin levels in women with systemic lupus erythematosus.

Authors:  Araceli Garcia-Gonzalez; Laura Gonzalez-Lopez; Isela C Valera-Gonzalez; Ernesto G Cardona-Muñoz; Mario Salazar-Paramo; Manuel González-Ortiz; Esperanza Martínez-Abundis; Jorge I Gamez-Nava
Journal:  Rheumatol Int       Date:  2002-06-27       Impact factor: 2.631

Review 10.  The pathophysiology of hypertension in systemic lupus erythematosus.

Authors:  Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-21       Impact factor: 3.619

View more
  20 in total

1.  Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.

Authors:  Keisa W Mathis; Erin B Taylor; Michael J Ryan
Journal:  Pharmacol Res       Date:  2017-04-08       Impact factor: 7.658

2.  Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.

Authors:  Victoria L Wolf; Taylor L Phillips; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

Review 3.  Understanding mechanisms of hypertension in systemic lupus erythematosus.

Authors:  Erin B Taylor; Michael J Ryan
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-03-15

Review 4.  Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.

Authors:  Elena Bartoloni; Alessia Alunno; Roberto Gerli
Journal:  Nat Rev Cardiol       Date:  2017-08-24       Impact factor: 32.419

Review 5.  Role of Inflammatory Diseases in Hypertension.

Authors:  E Bartoloni; A Alunno; V Valentini; F Luccioli; E Valentini; G La Paglia; O Bistoni; Roberto Gerli
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-09

6.  Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study.

Authors:  Jocelyn S Gandelman; Omair A Khan; Megan M Shuey; Jacquelyn E Neal; Elizabeth McNeer; Alyson Dickson; April Barnado; Li Wang; Prathima Anandi; William D Dupont; C Michael Stein; Cecilia P Chung
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-04       Impact factor: 4.794

7.  Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.

Authors:  Erin B Taylor; Michelle T Barati; David W Powell; Hannah R Turbeville; Michael J Ryan
Journal:  Hypertension       Date:  2018-01-29       Impact factor: 10.190

8.  Temporal hemodynamic changes in a female mouse model of systemic lupus erythematosus.

Authors:  Elena L Dent; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-09

9.  Blood pressure and albuminuria in a female mouse model of systemic lupus erythematosus: impact of long-term high salt consumption.

Authors:  Elena L Dent; Hanna J Broome; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-08-19       Impact factor: 3.619

Review 10.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Authors:  Cecilia Beatrice Chighizola; Voon H Ong; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 10.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.